tiprankstipranks

Aptose Biosciences price target lowered to $7 from $23 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Aptose Biosciences to $7 from $23 and keeps a Buy rating on the shares. The analyst cites the company’s ongoing financial needs as it is approaches its tuspetinib pivotal trial for the target cut.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue